Mdm2 inhibitors synergize with topoisomerase II inhibitors to induce p53-independent pancreatic cancer cell death

Network Modeling of MDM2 Inhibitor-Oxaliplatin Combination Reveals Biological Synergy in wt-p53 solid tumors

(2015) Asfar S. Azmi et al.   Oncotarget

Disclosure of Erlotinib as a Multikinase Inhibitor in Pancreatic Ductal Adenocarcinoma

(2015) Laura Conradt et al.   NEOPLASIA

MYC directs transcription of MCL1 and eIF4E genes to control sensitivity of gastric cancer cells toward HDAC inhibitors

(2012) Wajana L. Labisso et al.   CELL CYCLE

Dynamically regulated sumoylation of HDAC2 controls p53 deacetylation and restricts apoptosis following genotoxic stress

(2012) André Brandl et al.   Journal of Molecular Cell Biology

A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation

(2011) Jane M Valentine et al.   BMC CANCER

Translational approaches targeting the p53 pathway for anti-cancer therapy

(2011) Frank Essmann et al.   BRITISH JOURNAL OF PHARMACOLOGY

Use of the γ-H2AX assay to monitor DNA damage and repair in translational cancer research

(2011) Alesia Ivashkevich et al.   CANCER LETTERS

Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012

(2011) L Galluzzi et al.   CELL DEATH AND DIFFERENTIATION

Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells

(2011) Marc J. Rigatti et al.   MOLECULAR CARCINOGENESIS

MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function

(2010) Asfar S. Azmi et al.   EUROPEAN JOURNAL OF CANCER

The MRN complex in double-strand break repair and telomere maintenance

(2010) Brandon J. Lamarche et al.   FEBS LETTERS

The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor

(2010) J. J. Manfredi   GENES & DEVELOPMENT

IKK  controls canonical TGF -SMAD signaling to regulate genes expressing SNAIL and SLUG during EMT in Panc1 cells

(2010) M. Brandl et al.   JOURNAL OF CELL SCIENCE

Translating p53 into the clinic

(2010) Chit Fang Cheok et al.   Nature Reviews Clinical Oncology

Pancreatic Cancer

(2010) Manuel Hidalgo   NEW ENGLAND JOURNAL OF MEDICINE

Cross talk between stimulated NF-κB and the tumor suppressor p53

(2010) G Schneider et al.   ONCOGENE

A Simple and Cost-Effective Method to Transfect Small Interfering RNAs Into Pancreatic Cancer Cell Lines Using Polyethylenimine

(2010) Matthias Wirth et al.   PANCREAS

DNA damage response to the Mdm2 inhibitor Nutlin-3

(2009) Rajeev Verma et al.   BIOCHEMICAL PHARMACOLOGY

Mdm2 Affects Genome Stability Independent of p53

(2009) A. Bouska et al.   CANCER RESEARCH

Blinded by the Light: The Growing Complexity of p53

(2009) Karen H. Vousden et al.   CELL

Type II topoisomerases--inhibitors, repair mechanisms and mutations

(2009) P. Heisig   MUTAGENESIS

Murine double minute 2: p53-independent roads lead to genome instability or death

(2009) Alyssa Bouska et al.   TRENDS IN BIOCHEMICAL SCIENCES

TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use

(2009) M. Olivier et al.   Cold Spring Harbor Perspectives in Biology

Mdm2 Promotes Genetic Instability and Transformation Independent of p53

(2008) A. Bouska et al.   MOLECULAR AND CELLULAR BIOLOGY

Hdm2 is regulated by K-Ras and mediates p53-independent functions in pancreatic cancer cells

(2008) X Sui et al.   ONCOGENE

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

(2008) S. Shangary et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA